Drug · CHEMBL511142
BUPRENORPHINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BUPRENORPHINE. Drugs and targets, record CHEMBL511142. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL511142
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Brixadi, Bupeaze, Buplast, Butec, Butrans, Buvidal, Hapoctasin, Panitaz, Prenotrix, Reletrans, Sevodyne, Sublocade, Temgesic, Tephine, Transtec
- ChEMBL
- Other names
- BUPRENORPHINE COMPONENT OF ALKS-5461, Brixadi, Buprenorfina, Buprenorphin, Suboxone
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 38 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| OPRK1 | Kappa-type opioid receptor | Kappa opioid receptor agonist | AGONIST | https://conductscience.org/library/genes/4986 |
| OPRM1 | Mu-type opioid receptor | Mu opioid receptor agonist | AGONIST | https://conductscience.org/library/genes/4988 |
Source ChEMBL
Diseases38
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 38Source Open Targets
See all 38 diseasesTrials460
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 7 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 7 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02141399 | A Long-Term Safety Study of ALKS 5461 | Phase 3 | 1,485 | 2018-12-14 | alks 5461 | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT00315341 | Starting Treatment With Agonist Replacement Therapies (START) | Phase 4 | 1,269 | 2017-01-06 | buprenorphine | Its name | ClinicalTrials.gov |
| NCT00270257 | Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users | Phase 3 | 1,251 | 2016-12-08 | buprenorphine | Its name | ClinicalTrials.gov |
| NCT02946073 | Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain | Phase 3 | 1,053 | 2021-10-15 | buprenorphine | Its name | ClinicalTrials.gov |
| NCT03026790 | Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study | Phase 2 | 820 | 2023-06-05 | buprenorphine-naloxone | A combination that names it | ClinicalTrials.gov |
| NCT04995029 | Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users | Phase 4 | 785 | 2025-09-25 | buprenorphine | Its name | ClinicalTrials.gov |
| NCT02510014 | Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder | Phase 3 | 775 | 2018-03-29 | buprenorphine | Its name | ClinicalTrials.gov |
| NCT01908842 | Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults | Phase 3 | 759 | 2015-05-22 | buprenorphine | Its name | ClinicalTrials.gov |
| NCT01903005 | Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence | Phase 4 | 668 | 2015-10-28 | buprenorphine | Its name | ClinicalTrials.gov |
| NCT02357901 | Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine | Phase 3 | 665 | 2018-02-20 | buprenorphine, buprenorphine/naloxone | Its name | ClinicalTrials.gov |
1 to 10 of 460
See all 460 trialsComparisons in its trials175
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Long Term Medication Assisted Treatment (LT-MAT) vs Short Term Medication Assisted Treatment (ST-MAT): serious adverse events | 38 of 623 | 42 of 628 | 1,251 | NCT00270257 | Trial comparisons |
| Buprenorphine/Nx vs Methadone: serious adverse events | 38 of 727 | 45 of 520 | 1,247 | NCT00315341 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): 50% Reduction in Opioid Daily Dose | 102 of 403 | 98 of 399 | 802 | NCT03026790 | Trial comparisons |
| BNX Tablets, Then OL BNX Tablets, Then BNX Film vs Buprenorphine, Then OL BNX Film, Then BNX Tablets: serious adverse events | 3 of 383 | 1 of 375 | 758 | NCT01908842 | Trial comparisons |
| Induction Phase: Rapid Induction vs Induction Phase: Standard of Care Induction: Induction Phase: Number of Participants With Adverse Events up to Injection 2 | 202 of 474 | 93 of 255 | 729 | NCT04995029 | Trial comparisons |
| Induction Phase: Rapid Induction vs Induction Phase: Standard of Care Induction: Induction Phase: Percentage of Participants Receiving Injection 2 at the Week 2 Visit | 312 of 470 | 138 of 253 | 723 | NCT04995029 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): deaths from any cause | 7 of 358 | 9 of 363 | 721 | NCT03026790 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): serious adverse events | 109 of 358 | 109 of 363 | 721 | NCT03026790 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): Pain Response | 58 of 350 | 54 of 362 | 712 | NCT03026790 | Trial comparisons |
| Active Comparator: Telecare Collaborative Management (TCM) vs Active Comparator: Integrated Pain Team (IPT): Composite Response | 17 of 350 | 17 of 362 | 712 | NCT03026790 | Trial comparisons |
1 to 10 of 175
See all 175 comparisons in its trialsPapers from its trials245
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials17
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test B | 5 | 2 | ConductCognition |
| Trail Making Test A | 4 | 1 | ConductCognition |
| Delay Discounting | 3 | 0 | ConductCognition |
| Symbol Coding | 3 | 1 | ConductCognition |
| Verbal Fluency | 2 | 1 | ConductCognition |
| Card Sorting Test (Berg) | 1 | 1 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 0 | ConductCognition |
| Implicit Association Test (IAT) | 1 | 0 | ConductCognition |
| Iowa Gambling Lite | 1 | 0 | ConductCognition |
1 to 10 of 17
See all 17 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL511142
GET https://conductscience.org/api/drugs/v1/CHEMBL511142/diseases?page=2